questionnaires
OtherQuestionnaires: Rome III and IV criteria, GSRS, IBS-SSS, PHQ-9 and GAD-7
NCT Number: NCT07533968
This exploratory study investigates the impact of fertility treatments on symptoms of irritable bowel syndrome (IBS) in women. Specifically, the study focuses on two groups:
* Women with polycystic ovary syndrome (PCOS) who are starting their first IVF cycle. * Women who choose social freezing (freezing eggs for social reasons).
Background and Rationale PCOS is an endocrine disorder with hormonal and metabolic abnormalities associated with reduced fertility. There are four PCOS phenotypes, of which phenotypes A and B are the "classic" forms. Social freezing is becoming increasingly popular as an option for women without a partner who want to preserve their fertility.
IBS is a common gastrointestinal disorder involving motility disorders and a disturbed gut-brain axis. There is an increased risk of anxiety and depression in IBS patients. Women with PCOS have a twofold increased risk of developing IBS. However, little is known about the effect of hormonal fertility treatments on IBS symptoms.
Objectives
* Primary objective: To investigate whether fertility treatments influence the prevalence and severity of IBS symptoms. * Secondary objective: To investigate this change in IBS prevalence and severity in relation to: * Changes in anxiety and depression scores. * Changes in general gastrointestinal complaints. * Subgroup analyses based on: * Type of stimulation * Duration of desire to have children * Ethnicity * PCOS type * Hormonal and ultrasound response
Study design The study is a prospective, interventional exploratory study in which participants complete questionnaires before and after the hormonal stimulation phase.
* Start date : March 1, 2026 * End date of data collection: February 2027 * Participation locations: Fertility Clinic UZ Brussels * Target sample size: 120 women (60 per group)
Data collected
Before treatment:
* Demographics (height, weight, ethnicity) * Medical history related to fertility * PCOS phenotype (in study arm)
After treatment:
* Hormonal values (FSH, LH, estrogen, progesterone) * Number of follicles on ultrasound * Number of eggs collected
Questionnaires:
* IBS-SSS (IBS symptom severity) * Rome IV and III criteria (IBS diagnosis) * GSRS (general GI symptoms) * PHQ-9 (depression) * GAD-7 (anxiety)
Measuring instruments
* Rome IV and III criteria: Diagnosis of IBS based on frequency and nature of abdominal pain and changes in bowel movements. * IBS-SSS: Five dimensions of IBS symptoms, score between 0 and 500. * GSRS: General gastrointestinal complaints in five domains. * PHQ-9 and GAD-7: Validation instruments for depression and anxiety.
Data management
* Data is collected manually using paper questionnaires. * Data is then entered into RedCap. * Analysis is performed using SPSS. * Strict compliance with GDPR and confidentiality guidelines.
Statistical Analysis
* Logistic regression: To determine the likelihood of meeting the Rome criteria before and after treatment. * Multiple linear regression: To identify factors that influence change in IBS-SSS scores. * Model selection: Based on AIC (Akaike Information Criterion). * Separate analyses for PCOS and social freezing groups.
Trial opening soon.
Get Notified18 year and older
Female
Interventional
Not applicable
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Questionnaires: Rome III and IV criteria, GSRS, IBS-SSS, PHQ-9 and GAD-7
Time frame: "From start of ovarian stimulation to oocyte retrieval, up to 14 days"
Assessed using Rome III and Rome IV criteria. The number of participants meeting IBS diagnostic criteria will be compared before (at consultation) and after (at oocyte retrieval) ovarian stimulation.
Time frame: From start of ovarian stimulation to oocyte retrieval, up to 14 days"
Assessed using the IBS Severity Scoring System (IBS-SSS), a validated 5-item questionnaire. Total scores range from 0 to 500, with categories: remission (<75), mild (75-175), moderate (175-300), and severe (>300). The total IBS-SSS score will be compared before (at consultation) and after (at oocyte retrieval) ovarian stimulation.
Time frame: From start of ovarian stimulation to oocyte retrieval, up to 14 days"
"Assessed using the Gastrointestinal Symptom Rating Scale (GSRS), a validated 15-item questionnaire scored on a 7-point Likert scale. The total GSRS score will be compared before (at consultation) and after (at oocyte retrieval) ovarian stimulation."
Time frame: From start of ovarian stimulation to oocyte retrieval, up to 14 days
Assessed using the Patient Health Questionnaire (PHQ-9), a validated 9-item questionnaire. Total scores range from 0 to 27."
Time frame: From start of ovarian stimulation to oocyte retrieval, up to 14 days
Assessed using the Generalized Anxiety Disorder scale (GAD-7), a validated 7-item questionnaire. Total scores range from 0 to 21."
Time frame: From start of ovarian stimulation to oocyte retrieval, up to 14 days
Subgroup analyses will be performed to assess differences in IBS symptom severity (IBS-SSS and GSRS) based on: type of ovarian stimulation protocol, number of prior fertility treatments, duration of infertility, ethnicity, PCOS subtype, hormonal profile during controlled ovarian stimulation (estradiol, progesterone, LH, FSH), and ultrasound findings
Universitair Ziekenhuis Brussel
Other
Fertility Treatment: Impact on Symptoms of Irritable Bowel Syndrome
Acronym: FIBS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07687264
Adnexal Diseases, Body Weight
Zurich, Canton of Zurich, Switzerland
View Trial DetailsNCT07598344
Adnexal Diseases, Cysts
View Trial DetailsNCT07623551
Adnexal Diseases, Cysts
View Trial DetailsNCT07379502
Adnexal Diseases, Cysts
Khārian, Punjab Province, Pakistan
View Trial Details